The HCV Synthesis Project: Scope, methodology, and preliminary results
Author Information
Author(s): Rebecca K Stern, Holly Hagan, Corina Lelutiu-Weinberger, Don Des Jarlais, Roberta Scheinmann, Shiela Strauss, Enrique R Pouget, Peter Flom
Primary Institution: Center for Drug Use and HIV Research, National Development and Research Institutes (NDRI)
Hypothesis
What are the epidemiological factors associated with hepatitis C virus (HCV) transmission among drug users?
Conclusion
The data collection and quality assurance phases of the HCV Synthesis Project have been completed, leading to recommendations for future research on HCV in drug users.
Supporting Evidence
- 629 reports containing HCV prevalence rates, incidence rates, and/or genotype distribution were identified.
- The number of publications reporting HCV rates in drug users increased dramatically between 1989 and 2006.
- Recommendations for future research include clearly defining drug user participants and using standard reporting methods.
Takeaway
This study looked at how many people have hepatitis C among drug users and found a lot of information that can help us understand and prevent the disease better.
Methodology
The study synthesized research literature on HCV in drug users from 1989 to 2006, identifying and extracting data from published and unpublished reports.
Potential Biases
Potential biases due to the exclusion of studies that did not meet specific criteria for drug user populations.
Limitations
The study faced challenges such as lack of standard reporting of risk factor data and overlapping publication of data.
Participant Demographics
The majority of reports were from Western Europe (41%), North America (26%), Asia (11%), and Australia/New Zealand (10%).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website